- PR Newswire•2 days agoKindred Biosciences Submits New Animal Drug Application Technical Section for Effectiveness for Mirataz to FDA
SAN FRANCISCO, Aug. 22, 2016 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the submission of the Effectiveness Technical Section of the New Animal Drug Application for Mirataz™ (mirtazapine transdermal ointment) to the Food and Drug Administration (FDA) for the management of weight loss in cats. The Chemistry, Manufacturing, and Controls Technical Section was submitted in May 2016 and the Company plans to submit the Safety Technical Section in the third quarter of 2016.
- Associated Press•16 days ago
On a per-share basis, the Burlingame, California-based company said it had a loss of 25 cents. In the final minutes of trading on Monday, the company's shares hit $3.96. A year ago, they were trading at ...
Kindred Biosciences, Inc. (KIN)
NasdaqCM - NasdaqCM Real Time Price. Currency in USD
|Bid||4.24 x 800|
|Ask||4.25 x 200|
|Day's Range||4.20 - 4.38|
|52wk Range||2.90 - 6.38|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-3.44|
|Avg Vol (3m)||20,839|
|Dividend & Yield||N/A (N/A)|